BGV1 SIGNED
New vaccine for a paradigm shift in Brucellosis, one of the world’s most widespread zoonotic diseases affecting humans
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0BGV1 project word cloud
Explore the words cloud of the BGV1 project. It provides you a very rough idea of what is the project "BGV1" about.
Project "BGV1" data sheet
The following table provides information about the project.
| Coordinator |
BRUCELLA GREEN VAC SL
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Total cost | 2˙005˙250 € |
| EC max contribution | 1˙403˙675 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-EIC-SMEInst-2018-2020-3 |
| Funding Scheme | SME-2b |
| Starting year | 2020 |
| Duration (year-month-day) | from 2020-03-01 to 2022-02-28 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | BRUCELLA GREEN VAC SL | ES (MUTILVA) | coordinator | 1˙403˙675.00 |
Map
Project objective
Brucellosis is the world’s most widespread zoonotic disease. It is a global problem but most severely affects poor livestock keepers in the developing world because of its impacts on human and animal health and livelihoods. Brucellosis is endemic in most of Asia, Africa and Latin America and is prevalent in the EU Mediterranean regions. Currently vaccines for Brucellosis, around since the 1950s, suffer from serious safety drawbacks mainly due to residual virulence for animals and humans. Combined with rising antibiotic resistance, their use is relatively limited.
GreenVac is developing BGV1, the first vaccine in over 60 years against Brucella melitensis in small ruminants that overcomes the main drawbacks of existing vaccines. BGV1 has been designed to a) be avirulent for animals, b) eliminate interference with diagnostic tests after vaccination, c) have low potential transmissibility to humans and, d) be treatable with standard antibiotics. BGV1 is a strong candidate to replace the classic virulent vaccine, exhibiting a safe profile with an enhanced protective efficacy, no residual virulence and minimal serodiagnostic interference.
A successful BGV1 EU-project will allow, for the first time, mass vaccination of any animal at any time (including pregnant and lactating animals), which is a radical paradigm shift in Brucellosis control and eradication. The reduction of B. melitensis outbreaks and infection rate in animals will generate €3.81bn in cumulative economic benefits for users by 2028 by evading unnecessary diagnostics costs and losses caused by the infection. It will lead to a lower disease incidence in humans amidst ever rising globalisation and bioterrorism threats to anyone, anywhere. BGV1 will contribute to the objectives of the One Health Initiative: One World, One Health, One Medicine to improve the lives of all species through the integration of human medicine, veterinary medicine and environmental science.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BGV1" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BGV1" are provided by the European Opendata Portal: CORDIS opendata.